Inventor · disambiguated record
Thomas Craig Meagher
Also filed as: MEAGHER THOMAS · MEAGHER THOMAS CRAIG
8 granted patents·5 pending applications·10 citations·filing 2019–2025
81Inventor score
Technology areasA61K
Files withREGENERON PHARMA13
Top patents by PatentIndex Score
13 records- 0195US11725034B2IL2 agonists and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Aug 15, 2023·4 cites·30 claims
- 0291US12291559B2Compositions and methods for treating cancerREGENERON PHARMA·Filed 2023·Granted May 6, 2025·2 cites·15 claims
- 0391US11826386B2Compositions and methods for treating cancerREGENERON PHARMA·Filed 2021·Granted Nov 28, 2023·3 cites·21 claims
- 0488US2024400632A1Novel il2 agonists and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0587US12091440B2IL2 and peptide-MHC complex fusion proteins and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Sep 17, 2024·1 cites·33 claims
- 0687US2025034224A1Novel il2 agonists and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0785US12215131B2IgG Fc-IL2-Rα-IL2 fusions and methods of use thereofREGENERON PHARMA·Filed 2023·Granted Feb 4, 2025·0 cites·25 claims
- 0883US2023312665A1Novel il2 agonists and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0981US12319724B2IL2 agonists and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Jun 3, 2025·0 cites·13 claims
- 1071US2024325445A1Chimeric Antigen Receptors with BCMA Specificity and Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1168US2025223334A1Compositions and methods for treating cancerREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1265US12150959B2Chimeric antigen receptors with BCMA specificity and uses thereofREGENERON PHARMA·Filed 2019·Granted Nov 26, 2024·0 cites·25 claims
- 1354US12466870B2NY-ESO-1 T cell receptors and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Nov 11, 2025·0 cites·32 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →